Key result
Multiple new thrombin-inhibiting agents and antiplatelet therapies are now available as alternatives to unfractionated heparin for managing acute coronary syndrome.
This article discusses the availability of multiple new antithrombotic agents capable of inhibiting thrombin as alternatives to unfractionated heparin for ACS management.
Alternatives to UFH now available for ACS; leaves open optimal agent selection pending comparative trials.
A ntithrombotic therapy is central to the management of patients presenting with an acute coronary syndrome (ACS). In addition to powerful new antiplatelet therapies, multiple agents capable of inhibiting thrombin are now available to clinicians (Figure).
No takes yet. Share an insight, caveat, or question.
Elliott M. Antman (2001) studied this question. Multiple new thrombin-inhibiting agents and antiplatelet therapies are now available as alternatives to unfractionated heparin for managing acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: